Obinutuzumab (Afutuzumab)

  • #LGM Pharma is a Obinutuzumab (Afutuzumab) CAS# 949142-50-1 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 949142-50-1
  • AHFC code:
  • Synonyms: Afutuzumab, Afutuzumab [Previous USAN], GA 101, GA101, Gazyva, huMAB(CD20), huMAB, huMABCD20, Obinutuzumab, Ro 5072759, Ro5072759, UNII-O43472U9X8
  • ATC Code: L01XC15
  • Chemical Formula: C6512H10060N1712O2020S44
  • Molecular Weight: 146100 daltons
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB08935
  • InChl:
  • PubChem:
  • IUPAC:

Additional Details

Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
Obinutuzumab is more potent than rituximab in depleting B-cells, antitumor activity, and tumor regression.
Mode of Action:
In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.
Obinutuzumab is not metabolized by the liver.
The most serious toxicities observed with obinutuzumab are Hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML). HBV reactivation can occur with all anti-CD20 antibodies and can result in hepatic failure, fulminant hepatitis, and death. PML occurs as a result of JC virus infection and can be fatal as well. Other common but less serious adverse reactions include infusion reactions (pre-treat with glucocorticoids, acetaminophen, and anti-histamine to prevent this), neutropenia, thrombocytopenia, and Tumor Lysis Syndrome (TLS) (pre-treat patients, especially with a high lymphocyte count and/or a high tumor burden, with anti-hyperuricemics and hydration). It is also recommended to NOT administer live virus vaccinations prior to or during obinutuzumab treatment.
General Reference:
FDA label.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials


Related YouTube Videos